BUSINESS

• Japan CNS Market to Reach 648.7 Billion Yen in 2024: Fuji Keizai
  November 17, 2016

• First DOAC Antidote to Hit Japan Market This Month
  November 16, 2016

• Nipro Pharma Forms Capital Tie-Up with Vietnam’s Mekophar
  November 16, 2016

• Sawai Might See Teva-Takeda JV Impact on Distribution Channel: President
  November 15, 2016

• Ethical Drug Sales Down 5.6% in September: Crecon Report
  November 15, 2016

• Pace of Generic Substitution Slowing at Pharmacies: Sawai President
  November 15, 2016

• Regenerative Medicine Market to Expand to 142.1 Billion Yen in 2030: Fuji Keizai
  November 11, 2016

• Opdivo Significantly Prolongs OS in Gastric Cancer Patients in PIII Study: Ono
  November 11, 2016

• Takecab Most Promoted Drug in September: Anterio
  November 11, 2016

• Top 4 Wholesalers See Lower Sales in April-September If Hep C Meds Excluded
  November 11, 2016

• Enrollment Completed for PIII Adcetris Study for Mature T-Cell Lymphoma: Takeda
  November 10, 2016

• Nippon Shinyaku’s DMD Med Gets Fast Track Status in US
  November 10, 2016

• Kipres Generics Earn Bronchial Asthma Indication in Droves
  November 10, 2016

• MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
  November 10, 2016

• Takeda to Collaborate with 2 Universities on Application of Miniature Liver Technology to Drug Discovery Research
  November 10, 2016

• Kipres AG’s Market Penetration Faster than Expected: Kyorin President
  November 9, 2016

• Teva Takeda Pharma “Not a Threat” at Present: Nichi-Iko Pres. Tamura
  November 9, 2016

• BIKEN, Mitsubishi Tanabe to Form Vaccine JV Next May
  November 8, 2016

• Current Drug Pricing System Became Unfit for New Drugs Like Opdivo: Ono Chief
  November 8, 2016

• Ono's Revenue and Profits Soar as Opdivo Sales Jump 1,714%
  November 8, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 440
• 441
• 442
• 443
• 444
• 445
• 446
• 447
• 448
• …
• Next ›
• 最終 »